Aa
Normal vit D levels are associated with hbsag seroclearance.
Normal vitamin D levels are associated with spontaneous hepatitis B surface antigen seroclearance.
Mahamid M, Nseir W, Abu Elhija O, Shteingart S, Mahamid A, Smamra M, Koslowsky B.
Source
Mahmud Mahamid, Shimon Shteingart, Mosab Smamra, Benjamin Koslowsky, Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem 93722, Israel.
Abstract
AIM:
To investigate a possible association between serum vitamin D levels and spontaneous hepatitis B surface antigen (HBsAg) seroclearance.
METHODS:
Fifty-three patients diagnosed with chronic inactive hepatitis B and spontaneous HBsAg seroclearance were followed up in two Israeli liver units between 2007 and 2012. This retrospective study reviewed medical charts of all the patients, extracting demographic, serological and vitamin D rates in the serum, as well as medical conditions and current medical therapy. Spontaneous HBsAg seroclearance was defined as the loss of serum HBsAg indefinitely. Vitamin D levels were compared to all patients who underwent spontaneous HBsAg seroclearance.
RESULTS:
Out of the 53 patients who underwent hepatitis B antigen seroclearance, 44 patients (83%) had normal levels of 25-hydroxyvitamin vitamin D compared to 9 patients (17%) who had below normal levels. Multivariate analysis showed that age (> 35 years) OR = 1.7 (95%CI: 1.25-2.8, P = 0.05), serum vitamin D levels (> 20 ng/mL) OR = 2.6 (95%CI: 2.4-3.2, P = 0.02), hepatitis B e antigen negativity OR = 2.1 (95%CI: 2.2-3.1, P = 0.02), low viral load (hepatitis B virus DNA 8 years) OR = 1.6 (95%CI: 1.15-2.6, P = 0.04) were also associated with spontaneous HBsAg seroclearance.
CONCLUSION:
We found a strong correlation between normal vitamin D levels and spontaneous HBsAg seroclearance.
Mahamid M, Nseir W, Abu Elhija O, Shteingart S, Mahamid A, Smamra M, Koslowsky B.
Source
Mahmud Mahamid, Shimon Shteingart, Mosab Smamra, Benjamin Koslowsky, Digestive Disease Institute, Shaare Zedek Medical Center, Jerusalem 93722, Israel.
Abstract
AIM:
To investigate a possible association between serum vitamin D levels and spontaneous hepatitis B surface antigen (HBsAg) seroclearance.
METHODS:
Fifty-three patients diagnosed with chronic inactive hepatitis B and spontaneous HBsAg seroclearance were followed up in two Israeli liver units between 2007 and 2012. This retrospective study reviewed medical charts of all the patients, extracting demographic, serological and vitamin D rates in the serum, as well as medical conditions and current medical therapy. Spontaneous HBsAg seroclearance was defined as the loss of serum HBsAg indefinitely. Vitamin D levels were compared to all patients who underwent spontaneous HBsAg seroclearance.
RESULTS:
Out of the 53 patients who underwent hepatitis B antigen seroclearance, 44 patients (83%) had normal levels of 25-hydroxyvitamin vitamin D compared to 9 patients (17%) who had below normal levels. Multivariate analysis showed that age (> 35 years) OR = 1.7 (95%CI: 1.25-2.8, P = 0.05), serum vitamin D levels (> 20 ng/mL) OR = 2.6 (95%CI: 2.4-3.2, P = 0.02), hepatitis B e antigen negativity OR = 2.1 (95%CI: 2.2-3.1, P = 0.02), low viral load (hepatitis B virus DNA 8 years) OR = 1.6 (95%CI: 1.15-2.6, P = 0.04) were also associated with spontaneous HBsAg seroclearance.
CONCLUSION:
We found a strong correlation between normal vitamin D levels and spontaneous HBsAg seroclearance.
Thanks for posting it Stef. Excellent, I wish her fast recover and seroconversion,it would be nice advice for our future
my sister's experience:
vitd25oh>100ng/ml from sept 2013
oct 2013 150ng/ml
dec 2014 103ng/ml
apr 2014 108ng/ml
used gcmaf for about 2 months before starting tdf
started tdf dec 2013, baseline values: hbsag 13700iu/ml, hbvdna 1.600.000iu/ml
13 jan 2014 hbvdna 490iu/ml
08 apr 2014 hbsag 9000iu/ml, hbvdna und
response has been ultrafast on both hbvdna and surprise on hbsag too
vitd25oh>100ng/ml from sept 2013
oct 2013 150ng/ml
dec 2014 103ng/ml
apr 2014 108ng/ml
used gcmaf for about 2 months before starting tdf
started tdf dec 2013, baseline values: hbsag 13700iu/ml, hbvdna 1.600.000iu/ml
13 jan 2014 hbvdna 490iu/ml
08 apr 2014 hbsag 9000iu/ml, hbvdna und
response has been ultrafast on both hbvdna and surprise on hbsag too
http://bionews-tx.com/news/2014/03/06/arrowhead-receives-regulatory-approval-to-begin-phase-2a-trial-of-chronic-hepatitis-b-candidate-arc-520-non-texas-article/
Experimental Drug For Chronic Hepatitis B Cure ARC 520 to Begin Phase 2a Clinical Trial
Hepatitis B has been one of the leading causes of endemics throughout the world, with as many as 350 million cases reported. Among them, around 700,000 to 1.4 million cases have been reported in the USA alone, with an additional 5,000 to 8,000 cases of chronic infection being reported each year. Around one-third of the world’s population gets affected every year, with one million deaths reported annually. Once infected, the most common serological tests include those for the surface antigen of HBV (HBsAg), which is detectable within 1-6 months of infection, and the e antigen (HBeAg), which can be detected within 1-3 months from infection. Entecavir is one of the standard drugs used for treatment in HBV infections.
ARC 520 aims to deliver a functional cure for the HBV infection and restore the adaptive immune system with the help of its RNAi mechanism. It has been tested successfully in mice and chimpanzee models, where it has been shown to reduce the amount of viral DNA, HbsAg and HbeAg by as much as 90 – 95% , lasting up to one month or more.
On completing animal trials, a phase 1 human double blind, placebo controlled, dose escalating trial with a combination of ARC 520 and Entecavir was proposed and successfully executed. Arrowhead’s CEO and President, Dr. Christopher Anzalone, commented that, “We successfully completed enrollment in a Phase 1 clinical study in healthy volunteers with initial data indicating that ARC-520 is generally safe and well tolerated in humans. We will be filing with Hong Kong regulatory authorities this quarter to enable a Phase 2a study in patients with chronic HBV infection.”
The clinical trial will focus on an escalated intravenous dose of ARC 520 with a combination of Entecavir. The escalated dosage would have strengths of 1 mg/ Kg and 2 mg/Kg, and each will be used in cohort studies with 8 people, with 6 receiving ARC 520 and 2 receiving a placebo. The target demographic will be people aged between 15 – 65 years with immune active chronic HBV infection, HBV e antigen negativity, and ongoing Entecavir therapy.
The primary objective of the study will be to check the depth and duration of the decline of viral antigens and products in response to a stronger dose of ARC 520 along with Entecavir. Other factors to be tested through this include pharmacokinetic properties (safety, tolerance of patients) and pharmacodynamic properties (effects of the drug on HBV DNA serum titers and antibodies against HBV surface antigens).
Experimental Drug For Chronic Hepatitis B Cure ARC 520 to Begin Phase 2a Clinical Trial
Hepatitis B has been one of the leading causes of endemics throughout the world, with as many as 350 million cases reported. Among them, around 700,000 to 1.4 million cases have been reported in the USA alone, with an additional 5,000 to 8,000 cases of chronic infection being reported each year. Around one-third of the world’s population gets affected every year, with one million deaths reported annually. Once infected, the most common serological tests include those for the surface antigen of HBV (HBsAg), which is detectable within 1-6 months of infection, and the e antigen (HBeAg), which can be detected within 1-3 months from infection. Entecavir is one of the standard drugs used for treatment in HBV infections.
ARC 520 aims to deliver a functional cure for the HBV infection and restore the adaptive immune system with the help of its RNAi mechanism. It has been tested successfully in mice and chimpanzee models, where it has been shown to reduce the amount of viral DNA, HbsAg and HbeAg by as much as 90 – 95% , lasting up to one month or more.
On completing animal trials, a phase 1 human double blind, placebo controlled, dose escalating trial with a combination of ARC 520 and Entecavir was proposed and successfully executed. Arrowhead’s CEO and President, Dr. Christopher Anzalone, commented that, “We successfully completed enrollment in a Phase 1 clinical study in healthy volunteers with initial data indicating that ARC-520 is generally safe and well tolerated in humans. We will be filing with Hong Kong regulatory authorities this quarter to enable a Phase 2a study in patients with chronic HBV infection.”
The clinical trial will focus on an escalated intravenous dose of ARC 520 with a combination of Entecavir. The escalated dosage would have strengths of 1 mg/ Kg and 2 mg/Kg, and each will be used in cohort studies with 8 people, with 6 receiving ARC 520 and 2 receiving a placebo. The target demographic will be people aged between 15 – 65 years with immune active chronic HBV infection, HBV e antigen negativity, and ongoing Entecavir therapy.
The primary objective of the study will be to check the depth and duration of the decline of viral antigens and products in response to a stronger dose of ARC 520 along with Entecavir. Other factors to be tested through this include pharmacokinetic properties (safety, tolerance of patients) and pharmacodynamic properties (effects of the drug on HBV DNA serum titers and antibodies against HBV surface antigens).
Sorry there was a mistake in dna
Date/25(oh)/hbsag/dna/vit d3/1,25 oh
July/58/1590/<20/10000
Aug/64/1426/<20/10000
Sep/70/1891/86/10000
Nov/34/1856/56/5000/82
Dec/48/1907/50/10000/89
Feb/22/1530/<20/4000/75
Definately negative correlation vit D and hbsAg ....
Date/25(oh)/hbsag/dna/vit d3/1,25 oh
July/58/1590/<20/10000
Aug/64/1426/<20/10000
Sep/70/1891/86/10000
Nov/34/1856/56/5000/82
Dec/48/1907/50/10000/89
Feb/22/1530/<20/4000/75
Definately negative correlation vit D and hbsAg ....
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
our experience here might build a good evidence if many participate